CRISPR Therapeutics AG
For the period ended Dec 31, 2025. Filed Feb 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
From time to time, our officers (as defined in Rule 16a–1(f)) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended December 31, 2025, our officers and directors took the following actions with respect to Rule 10b5-1 trading arrangements:
| Name (Title) | Action Taken (Date of Action) | Type of Trading Arrangement | Nature of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|---|
| Katherine A. High, M.D. (Member of the Board of Directors) | Adoption(November 14, 2025) | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). | Sale of the Company’s common stock pursuant to the terms of the plan. | Active through March 12, 2027 | 22,000 |
| Simeon J. George, M.D. (Member of the Board of Directors) | Adoption(December 12, 2025) | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). | Sale of the Company’s common stock pursuant to the terms of the plan. | Active through April 13, 2027 | 116,000 |
| Naimish Patel, M.D. (Chief Medical Officer) | Adoption(December 16, 2025) | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). | Sale of the Company’s common stock pursuant to the terms of the plan. | Active through December 31, 2026 | 6,068 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.